Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1/2 10Phase 1 9Phase 3 2

Status

Completed 28Unknown 5Terminated 5Active not recruiting 2Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 1

Conditions

Breast Neoplasms 108Carcinoma, Non-Small-Cell Lung 95Prostatic Neoplasms 58Multiple Myeloma 45Neoplasms 38Neoplasm Metastasis 33Ovarian Neoplasms 26Melanoma 24Urinary Bladder Neoplasms 23Lung Neoplasms 22Colorectal Neoplasms 22Recurrence 21Leukemia, Lymphocytic, Chronic, B-Cell 21Parkinson Disease 4, Autosomal Dominant Lewy Body 20Carcinoma, Renal Cell 20Carcinoma, Hepatocellular 17Triple Negative Breast Neoplasms 16Nasopharyngeal Carcinoma 16Lymphoma, Non-Hodgkin 16Stomach Neoplasms 15Leukemia, Myeloid, Acute 15Lymphoma 14Squamous Cell Carcinoma of Head and Neck 13Small Cell Lung Carcinoma 13Fallopian Tube Neoplasms 12Colonic Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11

Interventions

decitabine and cedazuridine drug combination 1Lenalidomide 1Epoetin Alfa 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × Leukemia, Myelomonocytic, Chronic × Clear all
NCT00843882 2026-05-29

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
247 enrolled 19 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting
13 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡